The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Breast cancer is the most common malignancy in women worldwide. Metastasis is the
leading cause of high mortality in most cancers. Although predicting the early stage of breast …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Background Despite therapeutic advances in HER2-positive metastatic breast cancer,
resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Inflammation response of epithelial mucosa to chemo-radiotherapy cytotoxic effects leads to
mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated …